Dear Editor,

We read the article by Isha et al. published in Critical Care with great interest [1]. The authors conducted a retrospective cohort study to explore the correlation between inhaled nitric oxide (iNO) and mortality in COVID-19 patients. This study had an important cohort, and one of the key conclusions drawn from their research is that COVID-19 patients supported by HFNC/NIV may benefit from the iNO. However, we believe that some biases have not been adequately addressed.

First, this study lacks an analysis of immortal time bias [2]. It seems unlikely that patients in the iNO group would receive iNO immediately after being placed on HFNC. It is necessary to clarify the timing from patient enrollment (i.e., starting HFNC) to the initiation of iNO treatment. During this time period, patients in the iNO group are considered immortal, which can artificially extend the survival days of patients in the iNO group. Using the initiation of iNO as the starting point for patient enrollment to analyze the 28-day mortality rate is a viable approach.

Second, we observe that although the 28-day survival curves for the iNO group and the No-iNO group in the HFNC cohort show significant separation, the in-hospital mortality rates for the two groups are nearly identical (24.2% vs. 22.3% after matching, SMD = 0.046, p = 0.85 according to our calculations). In the Methods section, the authors describe using a Cox univariate regression model for survival analysis, making it unlikely that there would be a difference in in-hospital mortality rates. Based on this, we would like to further inquire whether the definition of mortality in Table 4 refers to the 28-day mortality rate (as described in Fig. 3) or in-hospital mortality, and whether adjustments were made for additional covariates.

Finally, we would like to point out that the discrepancy between the 28-day mortality rate in Fig. 3 and the matched in-hospital mortality rate in Table 1 may be due to the inhalation of NO delaying the progression of death in the spontaneously breathing group. However, this extension of survival time may not be meaningful, similar to how we occasionally observe patients receiving futile ECMO treatment, resulting in increased days of survival. If we analyze the survival curves at 90 days or 180 days, the curves may overlap again. Additionally, incorporating extubation or HFNC withdrawal as a competing risk for death would also be a viable approach to assess the differences in mortality due to respiratory failure between the two groups [3].

This cohort’s data is important; however, the authors must interpret the conclusion that COVID-19 patients supported by HFNC/NIV may benefit from the inhalation of NO with caution.

No datasets were generated or analysed during the current study.

1. Isha S, Balasubramanian P, Hanson AJ, et al. Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study. Crit Care. 2024;28:344.

   Article PubMed PubMed Central Google Scholar

2. Xu J, Zhong L, Shao H, et al. Incidence and clinical features of HHV-7 detection in lower respiratory tract in patients with severe pneumonia: a multicenter, retrospective study. Crit Care. 2023;27(1):248.

   Article PubMed PubMed Central Google Scholar

3. Jiang Y, Huang X, Zhou H, et al. Clinical characteristics and prognosis of patients with severe pneumonia with Pneumocystis jirovecii colonization: a multicenter. Retrosp Study Chest. 2024;S0012–3692(24):04841–4.

   Google Scholar

Download references

None.

Authors and Affiliations

1. Department of Critical Care Medicine, The First People’s Hospital of Pinghu, Pinghu, China

   Lin Zhong

2. Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

   Lingtong Huang

1. Lin ZhongView author publications

   You can also search for this author in PubMed Google Scholar

2. Lingtong HuangView author publications

   You can also search for this author in PubMed Google Scholar

Contributions

LZ and LTH participated in the discussion and wrote the manuscript.

Corresponding author

Correspondence to Lingtong Huang.

Ethics approval and consent to participate

None.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Zhong, L., Huang, L. Inhalation NO in the HFNC group may result in a meaningless extension of survival time. Crit Care 28, 370 (2024). https://doi.org/10.1186/s13054-024-05154-0

Download citation

• Received: 26 October 2024

• Accepted: 29 October 2024

• Published: 18 November 2024

• DOI: https://doi.org/10.1186/s13054-024-05154-0

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative